Form 4: Dyne Therapeutics COO Susanna Gatti High Sells Shares to Cover Tax Obligations

Dyne Therapeutics' Chief Operating Officer, Susanna Gatti High, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On September 11, 2024, Susanna Gatti High, the Chief Operating Officer of Dyne Therapeutics, sold 2,548 shares of common stock at a weighted average price of $31.89.
• An additional 2,722 shares were sold at the same weighted average price.
• These sales were executed to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs) granted on December 10, 2021, and December 9, 2022.
• The sales were conducted automatically as per the terms of the restricted stock unit agreement, aligning with Rule 10b5-1(c).
• Following these transactions, Susanna Gatti High beneficially owns 140,612 shares of Dyne Therapeutics common stock, which includes 123,429 unvested RSUs.
• The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports stock sales for tax purposes under a pre-existing plan, which is a routine event.

Positives

• The sales were part of a pre-arranged Rule 10b5-1 trading plan, indicating they were not based on insider information.

Industry Context

Sales of shares by company executives are a common occurrence, often related to compensation and tax obligations. The use of a 10b5-1 trading plan is a standard practice to avoid insider trading concerns.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among executives at publicly traded companies, including those in the biotechnology sector like Dyne Therapeutics.
• Comparable companies such as Sarepta Therapeutics or BioMarin Pharmaceutical also see similar filings related to executive stock transactions.
• The volume of shares sold is relatively small compared to the total outstanding shares of Dyne Therapeutics.

Stakeholder Impact

• The share sales are unlikely to have a significant impact on shareholders, as they are relatively small and part of a pre-arranged plan.
• Employees may be indirectly affected by the company's stock performance, but this transaction is unlikely to be a major driver.

Key Dates